IO102-IO103 (Cylembio®) + pembrolizumab

About IO Biotech

IO Biotech's mission is to develop immune-modulatory cancer vaccines that transform 'cold' tumors into 'hot,' immune-responsive environments. The company's lead candidate, IO102-IO103, has completed a pivotal Phase 3 trial in first-line advanced melanoma in combination with pembrolizumab. Its strategy leverages a differentiated T-win® platform to create combination-friendly, off-the-shelf therapies that could potentially enhance the efficacy of established immunotherapies.

Therapeutic Areas